Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911379 | 0.86 | AR (0.57) | AR | |
| SCHEMBL12056327 | 0.86 | AR (0.67) | AR | |
| SCHEMBL13945796 | 0.83 | KIF11 (0.44) | ARKIF11ALDH1A1HPGDALOX15 | |
| SCHEMBL497451 | 0.83 | KIF11 (0.47) | ARKIF11ALDH1A1HPGDALOX15 | |
| SCHEMBL30566936 | 0.83 | KIF11 (0.47) | ARKIF11ALDH1A1HPGDALOX15 | |
| SCHEMBL12724889 | 0.81 | TSHR (0.46) | ARKIF11ALDH1A1HPGDALOX15 | |
| SCHEMBL29397303 | 0.79 | KIF11 (0.44) | ARKIF11ALDH1A1 | |
| SCHEMBL8852317 | 0.79 | KIF11 (0.44) | ARKIF11ALDH1A1 | |
| SCHEMBL1799157 | 0.79 | ALDH1A1 (0.39) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL10256329 | 0.79 | AR (0.51) | ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046689-B2 | Selective estrogen receptor down-regulators | ASTRAZENECA AB (SE) | 2021-06-29 | — | — | US | disclosed |
| US-20200239468-A1 | Selective Estrogen Receptor Down-Regulators | ASTRAZENECA PHARMACEUTICALS LP | 2020-07-30 | — | — | US | disclosed |
| US-10590132-B2 | Selective estrogen receptor down-regulators | ASTRAZENECA AB (SE) | 2020-03-17 | — | — | US | disclosed |
| US-20190233413-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| US-10221173-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590132-B2 | Selective estrogen receptor down-regulators | ESR2, ESRRB, ESRRA | AR 14/4885KIF11 3176/4885ALDH1A1 1222/4885 |
| US-20190233413-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | AR 623/4885KIF11 1807/4885ALDH1A1 50/4885 |
| US-10221173-B2 | Chemical compounds | MKI67, CCNI, MCL1 | AR 623/4885KIF11 1807/4885ALDH1A1 50/4885 |
| US-11046689-B2 | Selective estrogen receptor down-regulators | ESR2, ESRRB, ESRRA | AR 14/4885KIF11 3176/4885ALDH1A1 1222/4885 |
| US-20200239468-A1 | Selective Estrogen Receptor Down-Regulators | ESR2, ESRRB, ESRRA | AR 14/4885KIF11 3176/4885ALDH1A1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.